Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 19/20 | 0.80 |
| ▸ | HDAC4 | P56524 | 19/20 | 0.80 |
| ▸ | HDAC1 | Q13547 | 19/20 | 0.80 |
| ▸ | HDAC7 | Q8WUI4 | 19/20 | 0.80 |
| ▸ | HDAC2 | Q92769 | 19/20 | 0.80 |
| ▸ | HDAC10 | Q969S8 | 19/20 | 0.80 |
| ▸ | HDAC11 | Q96DB2 | 19/20 | 0.80 |
| ▸ | HDAC8 | Q9BY41 | 19/20 | 0.80 |
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 0.80 |
| ▸ | HDAC9 | Q9UKV0 | 19/20 | 0.80 |
| ▸ | HDAC5 | Q9UQL6 | 19/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5315214 | 0.90 | HDAC3 (0.80) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8234467 | 0.90 | HDAC3 (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5337422 | 0.90 | HDAC3 (0.81) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5319344 | 0.89 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5320203 | 0.86 | HDAC3 (0.67) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8274005 | 0.82 | HDAC3 (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5318728 | 0.81 | HDAC3 (0.80) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5318461 | 0.80 | HDAC3 (0.67) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5318686 | 0.80 | HDAC3 (0.75) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8275611 | 0.80 | HDAC3 (0.71) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007067994-A1 | INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070135431-A1 | INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135431-A1 | INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135431-A1 | INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC (US) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135431-A1 | INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | HDAC6, HDAC1, HDAC3 | HDAC3 3/4885HDAC4 7/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.